Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

841. The influence of finasteride on the development of prostate cancer. Full Text available with Trip Pro

], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo.Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit (...) The influence of finasteride on the development of prostate cancer. Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer.In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA

2003 NEJM Controlled trial quality: predicted high

842. Brachytherapy for prostate cancer treatment

Brachytherapy for prostate cancer treatment Brachytherapy for prostate cancer treatment Brachytherapy for prostate cancer treatment Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia (...) Marti S. Brachytherapy for prostate cancer treatment. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives This study aims to provide an overview of the effectiveness of brachytherapy for prostate cancer treatment. Authors' conclusions If the therapeutic decision is to perform an active treatment (as opposed to observation and medical control), the patients should be appropriately informed of the scope and potential adverse effects

2003 Health Technology Assessment (HTA) Database.

843. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Hummel S, Paisley S, Morgan A, Currie E, Brewer N Citation Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost (...) -effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technology Assessment 2003; 7(33): 1-170 Authors' objectives

This report is a review of the clinical and cost-effectiveness of new and emerging technologies for early, localised prostate cancer. A systematic review was undertaken to identify new and emerging technologies and to evaluate clinical and cost-effectiveness through assessment of the best available evidence. The review aimed to assess

2003 Health Technology Assessment (HTA) Database.

844. Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer

Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Iskedjian M, Hemels M, Einarson T R, Vicente C, Iscoe N, Fleshner N Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Iskedjian M, Hemels M, Einarson T R, Vicente C, Iscoe N, Fleshner N. Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 65 Authors' objectives This report aims to review the clinical evidence for the use of luteinizing hormone-releasing hormone

2003 Health Technology Assessment (HTA) Database.

845. Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer

to stage localized prostate cancer is better than that of MRI alone, though the improvement seems to be modest. There is no information available on its effect on patient management or clinical outcomes. The use of superparamagnetic contrast material has been shown to increase the accuracy of MRI for lymph node metastases in prostate cancer. Improvements in the performance of MRI in imaging local prostatic disease might influence the potential usefulness of MRS as an additional test. Project page URL (...) Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D. Magnetic resonance

2003 Health Technology Assessment (HTA) Database.

846. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

for Cancer and Treatment (ProtecT) randomised trial of treatment has now been commissioned by the NHS R&D Health Technology Assessment Programme. It will be undertaken in nine clinical centres in the UK, involving over 100,000 men, and recruitment will take 5 years, commencing September 2001. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms /diagnosis Language Published English Country of organisation England Address (...) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study Prostate Testing for Cancer and Treatment (ProtecT) feasibility study Prostate Testing for Cancer and Treatment (ProtecT) feasibility study Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, Noble S, Lane A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2003 Health Technology Assessment (HTA) Database.

847. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

radiotherapy; cryotherapy; high-intensity focused ultrasound; interstitial microwave thermal therapy; transperianal radiofrequency interstitial tumour ablation; laser photocoagulation; gene therapy; high linear energy transfer radiation; radionuclide therapy; and vaccine therapy No studies of high linear energy transfer radiation, radionuclide therapy, or vaccine therapy were identified. Participants included in the review Studies of patients with early localised (T1 and T2) prostate cancer were eligible (...) Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Hummel S, Paisley S, Morgan A, Currie E, Brewer N CRD summary This review evaluated the effectiveness of new and emerging

2003 DARE.

848. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness

Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness Norderhaug I, Dahl O, Hoisaeter P A, Heikkila R, Klepp O, Olsen D R, Kristiansen I S, Waehre H, Johansen T E CRD summary This review compared brachytherapy with alternative approaches to prostate cancer treatment. The authors (...) concluded that the outcome of brachytherapy, external beam radiation and radical prostatectomy appears similar. The evidence presented supports the conclusion, but the quantity and quality of the evidence are limited. Authors' objectives To determine the effectiveness of brachytherapy for prostate cancer in comparison with alternative treatment approaches. Searching Existing systematic reviews were sought using the HTA database and the Cochrane Library, which the report implied covered studies from

2003 DARE.

849. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer

that was intracapsular (T1) or confined to the gland (T2), without detectable involvement of regional lymph nodes (N0-X), and of World Health Organization histologic grade 3; or patients who had had prostate cancer of any histologic grade that extended beyond the capsule (T3) or infiltrated neighbouring structures (T4) without involving regional lymph nodes. Patients with a prior malignant disease other than treated basal-cell carcinoma of the skin, and those with evidence of distant metastases (including metastases (...) Adenocarcinoma /drug therapy /economics /pathology /radiotherapy; Antineoplastic Agents, Hormonal /economics /therapeutic use; Capital Expenditures; Chemotherapy, Adjuvant /economics; Combined Modality Therapy /economics; Cost-Benefit Analysis; Drug Costs; Fees, Medical; Fees, Pharmaceutical; Goserelin /economics /therapeutic use; Hospital Costs; Humans; Male; Ontario; Prostatic Neoplasms /drug therapy /economics /pathology /radiotherapy; Radioisotope Teletherapy /economics; Randomized Controlled Trials

2003 NHS Economic Evaluation Database.

850. Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer

Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer Fujikawa K, Awakura Y, Okabe T, Watanabe R, Nishimura S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of androgen ablation therapy for metastatic prostate cancer. Five androgen ablation therapies were evaluated as first-line therapy: diethylstilbestrol diphosphate (DES), orchiectomy, orchiectomy plus nonsteroidal anti-androgen (NSAA), luteinising hormone-releasing hormone (LHRH) analogue, and LHRH analogue plus NSAA. Type of intervention Treatment. Economic study type Cost

2003 NHS Economic Evaluation Database.

851. Screening for prostate, breast and colorectal cancer in renal transplant recipients

Cancer Institute 1995;87:417-26. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /diagnosis; Computer Simulation; Cost-Benefit Analysis; Female; Guidelines as Topic; Humans; Kidney Transplantation /adverse effects /standards; Male; Mass Screening /economics /methods; Prostatic Neoplasms /diagnosis; Time Factors AccessionNumber 22003000904 Date bibliographic record published 29/02/2004 Date abstract record published 29/02/2004 NHS Economic Evaluation Database (NHS EED (...) Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Kiberd B A, Keough-Ryan T, Clase C M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2003 NHS Economic Evaluation Database.

852. Who can best recruit to randomized trials: randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)

Who can best recruit to randomized trials: randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study) Who can best recruit to randomized trials: randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study) Who can best recruit to randomized trials: randomized trial comparing surgeons and nurses recruiting patients to a trial (...) of treatments for localized prostate cancer (the ProtecT study) Donovan J L, Peters T J, Noble S, Powell P, Gillatt D, Oliver S E, Lane J A, Neal D E, Hamdy F C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of surgeons, compared

2003 NHS Economic Evaluation Database.

853. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer

Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

854. Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study Full Text available with Trip Pro

Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue

2003 NIHR HTA programme

855. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. (Abstract)

clinical detection. One study provides good evidence that radical prostatectomy reduces disease-specific mortality for men with localized prostate cancer detected clinically. No study has examined the additional benefit of earlier treatment after detection by screening. Men with a life expectancy of fewer than 10 years are unlikely to benefit from screening even under favorable assumptions. Each treatment is associated with several well-documented potential harms.Although potential harms of screening (...) Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. In U.S. men, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death. Screening for prostate cancer is controversial.To examine for the U.S. Preventive Services Task Force the evidence of benefits and harms of screening and earlier treatment.MEDLINE and the Cochrane Library, experts, and bibliographies of reviews.Researchers developed eight questions

2002 Annals of Internal Medicine

856. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. Full Text available with Trip Pro

Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. To explore the attitudes of men with confirmed or suspected prostate cancer to testing for prostate specific antigen.Qualitative interview study with a purposive sample.Great Britain.52 men with suspected or confirmed prostate cancer, recruited through general practitioners, urologists, patient support groups, and charities.Almost all men remembered their prostate specific antigen test (...) but recalled being given little information beforehand. Arguments in favour of increased access to testing included the belief that early diagnosis would reduce mortality, improve quality of life, and save the NHS money. Men also thought that a national screening programme should be available because symptoms can be ambiguous, screening for cancer is responsible health behaviour, and screening would encourage men to be tested. Four men who opposed a screening programme had gathered information alerting

2002 BMJ

857. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Full Text available with Trip Pro

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut.Natural experiment comparing two fixed cohorts from 1987 to 1997.Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results (...) areas.Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=120 621) areas.Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality.The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut, and the prostate biopsy rate was 2.20 (1.81 to 2.68) times that of Connecticut during 1987-90

2002 BMJ

858. Vasectomy and risk of prostate cancer. (Abstract)

Vasectomy and risk of prostate cancer. Vasectomy is a common method of contraception, but concern exists about a reported association with risk of prostate cancer.To examine whether vasectomy increases risk of prostate cancer.National population-based case-control study of 923 new cases of prostate cancer among men aged 40 to 74 years from the New Zealand Cancer Registry who were on the general electoral roll. Controls (n = 1224) were randomly selected from the general electoral roll (...) , with frequency matching to cases in 5-year age groups. Cases (3-15 months after diagnosis) and controls were interviewed by telephone between January 1997 and November 1999.Relative risk (RR) of prostate cancer for men who had had a vasectomy vs those who had not.There was no association between prostate cancer and vasectomy (RR, 0.92; 95% confidence interval [CI], 0.75-1.14) nor with time since vasectomy (RR, 0.92; 95% CI, 0.68-1.23 for > or = 25 years since vasectomy). Adjustment for social class

2002 JAMA

859. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. (Abstract)

in prostate cancer was confirmed by both RT-PCR and immunoblot analysis. Immunohistochemical analysis demonstrated an increased expression of AMACR in malignant prostate epithelia relative to benign epithelia. Tissue microarrays to assess AMACR expression in specimens consisting of benign prostate (n = 108 samples), atrophic prostate (n = 26), prostatic intraepithelial neoplasia (n = 75), localized prostate cancer (n = 116), and metastatic prostate cancer (n = 17) demonstrated mean AMACR protein staining (...) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens.To determine the expression and clinical utility of alpha-methylacyl coenzyme A racemase (AMACR), a gene identified as being overexpressed in prostate cancer by global profiling

2002 JAMA

860. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. (Abstract)

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Prostate cancer is a leading cause of cancer death in men. Treatment goals for men with advanced prostate cancer include prolonging survival, preventing or delaying symptoms due to disease progression, improving and maintaining quality of life, reducing treatment related morbidity. Androgen suppression therapy is considered a mainstay of treatment for men with advanced prostate cancer. However (...) , EMBASE, CancerLIT, Cochrane Library, VA Cochrane Prostate Disease register) and by reviewing bibliographies including those of the Blue Cross and Blue Shield Association Technology Evaluation Center/Evidence-based Practice Center of the Agency for Healthcare Research and Quality (BCBS/TEC-AHRQ) report No.4.All published randomized trials were eligible for inclusion provided they: randomized men with advanced prostate cancer to early versus deferred androgen suppression; reported overall, progression

2002 Cochrane